Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Horizon Therapeutics (NQ: HZNP )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Horizon Therapeutics

< Previous 1 2 3 4 5 6 7 8 Next >
Horizon Therapeutics plc Named as One of the Best Workplaces in Ireland
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Launches #RAREis Representation Program to Elevate Global Rare Disease Equity
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Initiates Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating Teprotumumab for the Treatment of Active Thyroid Eye Disease (TED)
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc to Present at the Cowen and Company 42nd Annual Health Care Conference
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Names Sean Clayton Executive Vice President and General Counsel
From Horizon Therapeutics plc
Via Business Wire
New Analysis Demonstrates UPLIZNA® (inebilizumab-cdon) Reduces Severity of Attacks Associated with Neuromyelitis Optica Spectrum Disorder (NMOSD)
From Horizon Therapeutics plc
Via Business Wire
New Post-Marketing Safety Analysis Shows Rate of Hearing-Related Events Associated with TEPEZZA® (teprotumumab-trbw) Comparable with Clinical Trial Observations
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Partners with the Doug the Pug Foundation and Sing Me A Story Foundation to Bring Awareness to Rare Diseases Impacting Children through #RAREis Playlist
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Named Title Partner of the Irish Open
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc to Release Fourth-Quarter and Full-Year 2021 Financial Results and Host Webcast on March 1, 2022
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2b Pivotal Trial Evaluating HZN-825 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Submits Supplemental Biologics License for the Concomitant Use of KRYSTEXXA® (pegloticase injection) Plus Methotrexate for People Living with Uncontrolled Gout
From Horizon Therapeutics plc
Via Business Wire
2022 Could be a Banner Year for Biotech Stocks as per top managers (SPRC, HOTH, NLSP, PSTV, IMMX, GNPX, NRBO)
Via AB Newswire
Horizon Therapeutics plc Announces Significant Expansion of East Coast Research and Development and Technical Operations Capability
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc to Participate in Upcoming Investor Conferences
From Horizon Therapeutics plc
Via Business Wire
Alpine Immune Sciences and Horizon Therapeutics plc Announce Exclusive License and Collaboration Agreement to Develop Novel Protein-Based Therapies for Autoimmune and Inflammatory Diseases
From Alpine Immune Sciences, Inc. and Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Makes $100,000 Seed Donation to Support Fundraising Efforts to Renovate Emmett Till’s Home into a Museum and Theater
From Horizon Therapeutics plc
Via Business Wire
Great Place to Work Names Horizon Therapeutics plc to Best Workplaces for Parents List
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Provides Academic Scholarships to Help Economically Disadvantaged Students in Ireland Further Their STEM Education
From Horizon Therapeutics plc
Via Business Wire
New Analysis Published in Multiple Sclerosis and Related Disorders Supports the Efficacy of UPLIZNA® (inebilizumab-cdon) in Patients Previously Treated with Rituximab for Neuromyelitis Optica Spectrum Disorder (NMOSD)
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics Recognizes Second Annual Thyroid Eye Disease (TED) Awareness Week with New Educational and Community Building Initiative
From Horizon Therapeutics plc
Via Business Wire
New Real-World Data Show High Rate of Patient Adherence to TEPEZZA® (teprotumumab-trbw) for Thyroid Eye Disease (TED)
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2b Pivotal Trial Evaluating HZN-825 for the Treatment of Diffuse Cutaneous Systemic Sclerosis
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc to Participate in Upcoming Investor Conferences
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Receives Top Workplace Awards in Chicago and San Francisco
From Horizon Therapeutics plc
Via Business Wire
Results from PROTECT Trial Evaluating KRYSTEXXA® (pegloticase injection) in Kidney Transplant Recipients with Uncontrolled Gout Presented as Part of American Society of Nephrology (ASN) Kidney Week
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Announces Chief Financial Officer Succession Plan
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Reports Record Third-Quarter 2021 Financial Results; Increasing Full-Year 2021 Net Sales and Adjusted EBITDA Guidance
From Horizon Therapeutics plc
Via Business Wire
New Data Being Presented at American College of Rheumatology Convergence 2021 Highlight Horizon’s Commitment to Improving Outcomes for People Living with Uncontrolled Gout
From Horizon Therapeutics plc
Via Business Wire
MIRROR Randomized Controlled Trial Meets Primary Endpoint and Shows 71% of Patients Achieved a Complete Response Rate Using KRYSTEXXA® (pegloticase injection) with Methotrexate
From Horizon Therapeutics plc
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.